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Background:  The best treatment strategy of coronary bifurcation stenosis is unknown.
Methods:  The dedicated bifurcation stent was created-bifurcation optimization stent system (BiOSS,Balton,Poland).The stent is a 316L stainless 
steel,coated with a biodegradable polymer and paclitaxel. The stent consists of two parts,with different diameters connected with 2 bridges.BiOSS 
is mounted on dedicated balloon (Bottle) with markers at the edges and 3rd marker at the mid part showing proximal end of smaller distal part.It 
is rapid exchange system.Provisional T-stenting was obligatory strategy. For optimization Bottle balloon with mid marker positioned at the SB ostium 
was used. Double antiplatelet therapy was planned for 12 months.
35 patients with non-left main bifurcation stenosis (n-LMB group)and 15 patients with left main (LM) bifurcation stenosis (LMB group) were included 
into the prospective, feasibility and safety study.The patients with STEMI and Medina type 001 bifurcation lesions were excluded. The primary end-
points of the study: death, myocardial infarction, in-stent thrombosis and target lesion revascularization (in-hospital, 1, 3, 6, 12 months after the 
intervention). An angiographic control is planned at 9 months. Here are presented the results up to the 6th month.
Results:  The average age of the enrolled patients (74% males) was 68±12 years.30(60%) patients had hypertension, 15(30%) were diabetic(5 
on insulin treatment). Almost two thirds(n=36) had previous NSTEMI treated with PCI, 9(18%) had previous STEMI treated with PCI. 6(12%) had 
previous CABG. In the LMB group(n=15) were: 6 with Medina type 111,5-010,three-110,1-011 types. In non-LMB group (n=35) the dominant vessel 
was LAD(n=20,57%),LCx (n=11,31%) and RCA (n=4,11%). The Medina type 111 lesions were in 49%(n=17). IVUS was performed in 37 cases (74%). 
All BiOSS stents were implanted successfully,without any periprocedural complication. There were only 7(14%)cases with second stent implanted 
within side branch. At 1 and 3 months all patients were uneventful (MACE rate 0%).
Conclusions:  The BiOSS bifurcation dedicated stent is a feasible device with promising safety and short-term clinical effectiveness/profile.
